SOCS5 contributes to temozolomide resistance in glioblastoma by regulating Bcl-2-mediated autophagy

References

• Kamil M, Shinsato Y, Higa N, et al. High filamin-C expression predicts enhanced invasiveness and poor outcome in glioblastoma multiforme. Br J Cancer. 2019;120(8):819–826.
   PubMed Web of Science ®Google Scholar
• Krieger T, Tirier SM, Park J, et al. Modeling glioblastoma invasion using human brain organoids and single-cell transcriptomics. Neuro Oncol. 2020;22(8):1138–1149.
   PubMed Web of Science ®Google Scholar
• De Witt Hamer P, Ho VKY, Zwinderman AH, et al. Between-hospital variation in mortality and survival after glioblastoma surgery in the Dutch quality registry for neuro surgery. J Neurooncol. 2019;144(2):313–323.
   PubMed Web of Science ®Google Scholar
• Butterbrod E, Synhaeve N, Rutten G-J, et al. Cognitive impairment three months after surgery is an independent predictor of survival time in glioblastoma patients. J Neurooncol. 2020;149(1):103–111.
   PubMed Web of Science ®Google Scholar
• Wong B, Shah SR, Yankaskas CL, et al. A microfluidic cell-migration assay for the prediction of progression-free survival and recurrence time of patients with glioblastoma. Nat Biomed Eng. 2021;5(1):26–40.
   PubMed Web of Science ®Google Scholar
• Wang Y, Feng Y. The efficacy and safety of radiotherapy with adjuvant temozolomide for glioblastoma: a meta-analysis of randomized controlled studies. Clin Neurol Neurosurg. 2020;196:105890.
   PubMed Web of Science ®Google Scholar
• Karachi A, Dastmalchi F, Mitchell DA, et al. Temozolomide for immunomodulation in the treatment of glioblastoma. Neuro Oncol. 2018;20(12):1566–1572.
   PubMed Web of Science ®Google Scholar
• McAleenan A, Kelly C, Spiga F, et al. Prognostic value of test(s) for O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide. Cochrane Database Syst Rev. 2021; 3:013316. 10.1002/14651858.CD013316.pub2.
   Google Scholar
• Aoki K, Natsume A. Overview of DNA methylation in adult diffuse gliomas. Brain Tumor Pathol. 2019;36(2):84–91.
   PubMed Web of Science ®Google Scholar
• He Y, Kaina B. Are there thresholds in glioblastoma cell death responses triggered by temozolomide? Int J Mol Sci. 2019;20(7):1562.
   PubMed Web of Science ®Google Scholar
• Ito M, Ohba S, Gaensler K, et al. Early Chk1 phosphorylation is driven by temozolomide-induced, DNA double strand break- and mismatch repair-independent DNA damage. PloS one. 2013;8(5):e62351.
   PubMed Web of Science ®Google Scholar
• Zhang B, Xu C, Liu J, et al. Nidogen-1 expression is associated with overall survival and temozolomide sensitivity in low-grade glioma patients. Aging (Albany NY). 2021;13(6):9085–9107.
   PubMedGoogle Scholar
• Sorribes I, Handelman S, Jain H. Mitigating temozolomide resistance in glioblastoma via DNA damage-repair inhibition. J R Soc Interface. 2020;17(162):20190722.
   PubMed Web of Science ®Google Scholar
• Jiapaer S, Furuta T, Tanaka S, et al. Potential strategies overcoming the temozolomide resistance for glioblastoma. Neurologia medico-chirurgica. 2018;58(10):405–421.
   PubMed Web of Science ®Google Scholar
• Devis-Jauregui L, Eritja N, Davis ML, et al. Autophagy in the physiological endometrium and cancer. Autophagy. 2021;17(5):1077–1095.
   PubMed Web of Science ®Google Scholar
• Luo X, Qiu Y, Dinesh P, et al. The functions of autophagy at the tumour-immune interface. J Cell Mol Med. 2021;25(5):2333–2341.
   PubMed Web of Science ®Google Scholar
• Xia H, Green D, Zou W. Autophagy in tumour immunity and therapy. Nature reviews Cancer. 2021;21(5):281–297.
   PubMed Web of Science ®Google Scholar
• Lu H, Xiao J, Ke C, et al. TOPK inhibits autophagy by phosphorylating ULK1 and promotes glioma resistance to TMZ. Cell Death Dis. 2019;10(8):583.
   PubMedGoogle Scholar
• Harder B, Peng S, Sereduk CP, et al. Inhibition of phosphatidylinositol 3-kinase by PX-866 suppresses temozolomide-induced autophagy and promotes apoptosis in glioblastoma cells. Mol Med. 2019;25(1):49.
   PubMed Web of Science ®Google Scholar
• Cooney R. Suppressors of cytokine signaling (SOCS): inhibitors of the JAK/STAT pathway. Shock (Augusta,Ga.). 2002;17(2):83–90
   PubMed Web of Science ®Google Scholar
• Huang S, Liu K, Cheng A, et al. SOCS proteins participate in the regulation of innate immune response caused by viruses. Front Immunol. 2020;11:558341.
   PubMed Web of Science ®Google Scholar
• Yang P, Chang Y-H, Wong L-F, et al. The genetic effect and molecular function of the SOCS5 in the prognosis of esophageal squamous cell carcinoma. J Cancer. 2021;12(8):2216–2229.
   PubMed Web of Science ®Google Scholar
• Yan D, Jin F, Lin Y. lncRNA HAND2-AS1 Inhibits liver cancer cell proliferation and migration by upregulating SOCS5 to inactivate the JAK-STAT pathway. Cancer Biother Radiopharm. 2020;35(2):143–152.
   PubMed Web of Science ®Google Scholar
• Fan G, Jiao J, Shen F, et al. Long non-coding RNA HCG11sponging miR-522-3p inhibits the tumorigenesis of non-small cell lung cancer by upregulating SOCS5. Thorac Cancer. 2020;11(10):2877–2886.
   PubMedGoogle Scholar
• Hu H, Zhang Q, Chen W, et al. MicroRNA-301a promotes pancreatic cancer invasion and metastasis through the JAK/STAT3 signaling pathway by targeting SOCS5. Carcinogenesis. 2020;41(4):502–514.
   PubMed Web of Science ®Google Scholar
• Liu Z, Wang J, Tong H, et al. LINC00668 Modulates SOCS5 Expression Through Competitively Sponging miR-518c-3p to facilitate glioma cell proliferation. Neurochem Res. 2020;45(7):1614–1625.
   PubMed Web of Science ®Google Scholar
• Zhang N, Wu X, Yang L, et al. FoxM1 inhibition sensitizes resistant glioblastoma cells to temozolomide by downregulating the expression of DNA-Repair GeneRad51. Clin Cancer Res off J Am Assoc Cancer Res. 2012;18(21):5961–5971.
   PubMed Web of Science ®Google Scholar
• Jin Y, Zuo HX, Li MY, et al. Anti-Tumor effects of carrimycin and monomeric isovalerylspiramycin i on hepatocellular carcinoma in vitro and in vivo. Front Pharmacol. 2021;12:774231.
   PubMed Web of Science ®Google Scholar
• Pan J, Li M, Yu F, et al. Up-Regulation of p53/miR-628-3p pathway, a novel mechanism of shikonin on inhibiting proliferation and inducing apoptosis of A549 and PC-9 Non-Small Cell Lung Cancer Cell Lines. Front Pharmacol. 2021;12:766165.
   PubMed Web of Science ®Google Scholar
• Singh T, Chhokar A, Thakur K, et al. Berberis aquifoliumTargeting aberrant expression of STAT3 and AP-1 oncogenic transcription factors and HPV oncoproteins in cervical cancer by. Front Pharmacol. 2021;12:757414.
   PubMed Web of Science ®Google Scholar
• Cordani M, Somoza Á, Tafani M, et al. Editorial: novel cancer treatments based on autophagy modulation. Front Pharmacol. 2021;12:650559.
   PubMed Web of Science ®Google Scholar
• Stackhouse C, Gillespie G, Willey C. Exploring the Roles of lncRNAs in GBM pathophysiology and their therapeutic potential. Cells. 2020;9(11):11.
   Web of Science ®Google Scholar
• Tang L, Feng Y, Gao S, et al. Nanotherapeutics overcoming the blood-brain barrier for glioblastoma treatment. Front Pharmacol. 2021;12:786700.
   PubMed Web of Science ®Google Scholar
• Kuwayama K, Matsuzaki K, Mizobuchi Y, et al. Promyelocytic leukemia protein induces apoptosis due to caspase-8 activation via the repression of NFkappaB activation in glioblastoma. Neuro Oncol. 2009;11(2):132–141.
   PubMed Web of Science ®Google Scholar
• Lindemann C, Hackmann O, Delic S, et al. SOCS3 promoter methylation is mutually exclusive to EGFR amplification in gliomas and promotes glioma cell invasion through STAT3 and FAK activation. Acta Neuropathol. 2011;122(2):241–251.
   PubMed Web of Science ®Google Scholar
• Tomita S, Ishibashi K, Hashimoto K, et al. Suppression of SOCS3 increases susceptibility of renal cell carcinoma to interferon-α. Cancer Sci. 2011;102(1):57–63.
   PubMed Web of Science ®Google Scholar
• Sakai I, Takeuchi K, Yamauchi H, et al. Constitutive expression of SOCS3 confers resistance to IFN-α in chronic myelogenous leukemia cells. Blood. 2002;100(8):2926–2931.
   PubMed Web of Science ®Google Scholar
• Zhang M, Liu S, Chua M-S, et al. SOCS5 inhibition induces autophagy to impair metastasis in hepatocellular carcinoma cells via the PI3K/Akt/mTOR pathway. Cell Death & Disease. 2019;10(8):612.
   PubMedGoogle Scholar
• Sanchez-Mejias A, Kwon J, Chew XH, et al. A novel SOCS5/miR-18/miR-25 axis promotes tumorigenesis in liver cancer. International Journal of Cancer. 2019;144(2):311–321.
   PubMed Web of Science ®Google Scholar
• Guo W, Li W, Yuan L, et al. MicroRNA-106a-3p induces apatinib resistance and activates janus-activated kinase 2 (JAK2)/Signal Transducer and Activator of Transcription 3 (STAT3) by Targeting the SOCS System in Gastric Cancer. Med Sci Monit. 2019;25:10122–10128.
   PubMed Web of Science ®Google Scholar
• Zamame Ramirez J, Romagnoli G, Kaneno R. Inhibiting autophagy to prevent drug resistance and improve anti-tumor therapy. Life Sci. 2021;265:118745.
   PubMed Web of Science ®Google Scholar
• Smith A, Macleod K. Autophagy, cancer stem cells and drug resistance. J Pathol. 2019;247(5):708–718.
   PubMed Web of Science ®Google Scholar
• Yun E, Kim S, Hsieh J-T, et al. Wnt/β-catenin signaling pathway induces autophagy-mediated temozolomide-resistance in human glioblastoma. Cell Death Dis. 2020;11(9):771.
   PubMed Web of Science ®Google Scholar
• Li H, Chen L, Li -J-J, et al. miR-519a enhances chemosensitivity and promotes autophagy in glioblastoma by targeting STAT3/Bcl2 signaling pathway. J Hematol Oncol. 2018;11(1):70.
   PubMedGoogle Scholar
• Pattingre S, Tassa A, Qu X, et al. Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell. 2005;122(6):927–939.
   PubMed Web of Science ®Google Scholar
• Levine B, Sinha S, Kroemer G. Bcl-2 family members: dual regulators of apoptosis and autophagy. Autophagy. 2008;4(5):600–606.
   PubMed Web of Science ®Google Scholar
• Gordy C, He YW. The crosstalk between autophagy and apoptosis: where does this lead? Protein Cell. 2012;3(1):17–27.
   PubMed Web of Science ®Google Scholar